FORMYCON AG
BiotechFORMYCON AG is a biotechnology company focused on Ophthalmology, Oncology.
FORMYCON AG's Key Drugs
FORMYCON AG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
FORMYCON AG's Recent FDA Approvals
FORMYCON AG secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
FORMYCON AG's Therapeutic Areas
FORMYCON AG's approved drugs and pipeline span 2 therapeutic areas, led by Ophthalmology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FORMYCON AG's Top Competitors
FORMYCON AG's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FORMYCON AG Pipeline Snapshot
FORMYCON AG has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2024-06-28
- Latest
- 2025-12-18
- Applications
- 2